However, subsequent meta-analyses of more recently completed RCTs including RECOVERY, or even unpublished data through searches of electronic databases and contact with experts, ultimately concluded that, in patients hospitalised with COVID-19, treatment with IL-6 antagonists, and in particular tocilizumab (with much higher certainty than sarilumab, but not siltuximab), results into a significant reduction in 28-day all-cause mortality (2, 32, 58), in line with previous meta-analyses of observational cohort studies (22, 77, 78). Here, IL6 is linked to COVID-19.